292,747 Roivant Sciences Ltd. $ROIV Shares Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 14.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,697,763 shares of the company’s stock after selling 292,747 shares during the period. Candriam S.C.A.’s holdings in Roivant Sciences were worth $62,314,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ROIV. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Roivant Sciences during the second quarter valued at about $2,166,000. Squarepoint Ops LLC bought a new stake in shares of Roivant Sciences in the second quarter valued at about $16,830,000. Arizona State Retirement System lifted its stake in shares of Roivant Sciences by 24.4% in the second quarter. Arizona State Retirement System now owns 128,364 shares of the company’s stock valued at $4,543,000 after buying an additional 25,199 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in Roivant Sciences during the first quarter worth about $3,957,000. Finally, Bank of America Corp DE grew its position in Roivant Sciences by 8.0% during the first quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock worth $87,638,000 after buying an additional 235,493 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $38.88 on Friday. Roivant Sciences Ltd. has a 52-week low of $19.79 and a 52-week high of $42.50. The stock has a market cap of $28.08 billion, a price-to-earnings ratio of -73.36 and a beta of 1.23. The firm has a fifty day moving average of $36.69 and a 200-day moving average of $31.80.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. Guggenheim raised their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. UBS Group set a $55.00 price objective on Roivant Sciences in a research report on Wednesday, September 9th. Citigroup lifted their price objective on Roivant Sciences from $46.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, Jefferies Financial Group boosted their price objective on Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.55.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $36.31, for a total transaction of $7,262,000.00. Following the completion of the transaction, the chief executive officer owned 999,154 shares in the company, valued at $36,279,281.74. This trade represents a 16.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88. Following the sale, the insider directly owned 18,630,739 shares in the company, valued at $679,649,358.72. The trade was a 0.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 2,022,688 shares of company stock valued at $73,438,636 over the last quarter. 8.80% of the stock is owned by company insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases.

Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

Roivant operates internationally, with activities spanning the United States and other markets.